An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Vutrisiran (Amvuttra): CADTH Reimbursement Recommendation: Indication: For the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb.
Top results in this bookTable of Contents
CADTH Canadian Drug Expert Committee Recommendation: Patisiran (Onpattro — Alnylam Netherlands BV): Indication: For the treatment of polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jul.
Elranatamab (Elrexfio): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jun.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
CADTH Reimbursement Reviews and Recommendations.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013-.
Suspected neurological conditions: recognition and referral.
National Guideline Centre (UK).
London: National Institute for Health and Care Excellence (NICE); 2019 May. (NICE Guideline, No. 127.)
Tafamidis Meglumine (Vyndaqel): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on